News

AbCheck licenses mAB technology
Enlarge image

BusinessCzech Republic

AbCheck licenses mAB technology

14.11.2012 - Plzen-based AbCheck s.r.o.has licensed an affinity maturation and antibody optimisation platform from US bioinformatics company Distributed Bio LCC.

Under the terms of the exclusive, worldwide agreement, AbCheck will apply Distributed Bio LCC’s proprietary computational library design algorithms to address the affinity maturation, therapeutic 'developability' and stability optimisation of antibodies in a one-step process.  According to the Czech antibody specialist, the platform of the US bioinformatics specialist makes it possible to deliver functional, "GMP ready", antibodies with significantly increased affinities with minimal mutations from fully human frameworks from its phage and yeast display antibody libraries

AbCheck CEO Volker Lang stressed: "By combining the strength of both technologies we have created a platform that exactly addresses current market needs.“ "Library design algorithms redefine the full potential of high throughput screening," said Jacob Glanville, Scientific Director of Distributed Bio. "Distributed Bio's library design algorithms encode years of protein engineering directly into the library designs. We are delighted to bring this technology forward with AbCheck: their leading edge expertise in antibody engineering and library development make them an ideal partner for introducing this new technology to the market.

Abcheck uses its AbSieve platform to develop antibodies for partners in all antibody formats, and its AbAccel algorithm for affinity maturation and optimisation. Distributed Bio provides antibody informatics, including: sequence & structural analysis; affinity maturation & humanisation; NextGen repertoire sequencing; phage display panning and library analysis.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/abcheck-licenses-antibody-technology.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • PROTHENA PLC (IE)52.22 USD47.2%
  • FLAMEL TECHNOLOGIES (F)12.58 USD33.1%
  • DBV TECHNOLOGIES (F)64.40 EUR26.3%

FLOP

  • MOLOGEN (D)1.75 EUR-30.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.62 GBP-19.5%

TOP

  • KARO BIO (S)29.80 SEK1774.2%
  • NICOX (F)11.20 EUR474.4%
  • SAREUM HOLDINGS (UK)0.62 GBP158.3%

FLOP

  • BB BIOTECH (D)45.00 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.9%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016